Trial watch: TLR3 agonists in cancer therapy.

Julie Le NaourLorenzo Galluzzi Laurence Zitvogel Guido KroemerErika Vacchelli

Published in: Oncoimmunology (2020)

cDC, conventional dendritic cell; CMT, cytokine modulating treatment; CRC, colorectal carcinoma; CTL, cytotoxic T lymphocyte; DC, dendritic cell; dsRNA, double-stranded RNA; FLT3LG, fms-related receptor tyrosine kinase 3 ligand; HNSCC, head and neck squamous cell carcinoma; IFN, interferon; IL, interleukin; ISV, in situ vaccine; MUC1, mucin 1, cell surface associated; PD-1, programmed cell death 1; PD-L1, programmed death-ligand 1; polyA:U, polyadenylic:polyuridylic acid; polyI:C, polyriboinosinic:polyribocytidylic acid; TLR, Toll-like receptor.

Keyphrases

dendritic cells
tyrosine kinase
toll like receptor
immune response
cell surface
epidermal growth factor receptor
cancer therapy
inflammatory response
nuclear factor
regulatory t cells
binding protein
clinical trial
study protocol
phase iii
peripheral blood
phase ii
randomized controlled trial
smoking cessation